Lexicon Pharmaceuticals (LXRX) Projected to Post Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 5:00 PM ET.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX stock opened at $1.50 on Thursday. Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $1.83. The company has a market capitalization of $545.21 million, a price-to-earnings ratio of -7.89 and a beta of 0.98. The company has a 50-day simple moving average of $1.31 and a 200 day simple moving average of $1.31. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.63 and a current ratio of 5.64.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $3.23.

Insiders Place Their Bets

In related news, Director Raymond Debbane purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were bought at an average price of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the transaction, the director owned 1,904,186 shares of the company’s stock, valued at approximately $2,799,153.42. This trade represents a 5.54% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Invus Global Management, Llc purchased 1,538,462 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was bought at an average cost of $1.30 per share, with a total value of $2,000,000.60. Following the purchase, the director owned 1,538,462 shares of the company’s stock, valued at $2,000,000.60. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 1,788,462 shares of company stock worth $2,367,001. Corporate insiders own 13.90% of the company’s stock.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Lexicon Pharmaceuticals by 7.6% during the 3rd quarter. Vanguard Group Inc. now owns 9,521,874 shares of the biopharmaceutical company’s stock worth $12,855,000 after acquiring an additional 670,838 shares in the last quarter. Millennium Management LLC lifted its stake in Lexicon Pharmaceuticals by 25.9% during the fourth quarter. Millennium Management LLC now owns 4,821,733 shares of the biopharmaceutical company’s stock worth $5,545,000 after purchasing an additional 991,073 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Lexicon Pharmaceuticals by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 2,500,022 shares of the biopharmaceutical company’s stock valued at $2,876,000 after purchasing an additional 102,099 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $3,240,000. Finally, Marshall Wace LLP acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth $1,452,000. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.